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Hereditary Hemorrhagic Telangiectasia type-1 (HHT1) is a genetic vascular disorder caused
by haploinsufficiency of the TGFβ co-receptor endoglin. Dysfunctional homing of HHT1
mononuclear cells (MNCs) towards the infarcted myocardium hampers cardiac recovery.
HHT1-MNCs have elevated expression of dipeptidyl peptidase-4 (DPP4/CD26), which
inhibits recruitment of CXCR4-expressing MNCs by inactivation of stromal cell-derived fac-
tor 1 (SDF1). We hypothesize that inhibiting DPP4 will restore homing of HHT1-MNCs to the
infarcted heart and improve cardiac recovery.
Methods and results
After inducing myocardial infarction (MI), wild type (WT) and endoglin heterozygous (Eng+/-)
mice were treated for 5 days with the DPP4 inhibitor Diprotin A (DipA). DipA increased the
number of CXCR4+ MNCs residing in the infarcted Eng+/- hearts (Eng+/- 73.17±12.67 vs.
Eng+/- treated 157.00±11.61, P = 0.0003) and significantly reduced infarct size (Eng+/- 46.60
±9.33% vs. Eng+/- treated 27.02±3.04%, P = 0.03). Echocardiography demonstrated that
DipA treatment slightly deteriorated heart function in Eng+/- mice. An increased number of
capillaries (Eng+/- 61.63±1.43 vs. Eng+/- treated 74.30±1.74, P = 0.001) were detected in the
infarct border zone whereas the number of arteries was reduced (Eng+/- 11.88±0.63 vs.
Eng+/- treated 6.38±0.97, P = 0.003). Interestingly, while less M2 regenerative macrophages
were present in Eng+/- hearts prior to DipA treatment, (WT 29.88±1.52% vs. Eng+/- 12.34
±1.64%, P<0.0001), DPP4 inhibition restored the number of M2 macrophages to wild type
levels.
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Conclusions
In this study, we demonstrate that systemic DPP4 inhibition restores the impaired MNC
homing in Eng+/- animals post-MI, and enhances cardiac repair, which might be explained
by restoring the balance between the inflammatory and regenerative macrophages present
in the heart.
Introduction
Hereditary Hemorrhagic Telangiectasia type 1 (HHT1) is a haploinsufficient genetic vascular
disorder caused by mutations in the transforming growth factor beta (TGFβ) co-receptor
endoglin (CD105). HHT1 is characterized by ’leaky’ vessel formation due to impaired TGFβ
signaling, demonstrated by internal organ bleeding, endothelial hyperplasia, arteriovenous
malformations (AVMs) and recurrent epistaxis, up to 8 times a day [1, 2]. Interestingly, endo-
glin heterozygous mice (Eng+/-) can develop the same clinical features as HHT1 patients [3, 4].
In time, depending on the genetic background [5], Eng+/- mice develop AVMs clearly visible
in the ear, and even suffer from nosebleeds, making the Eng+/- mouse a good experimental
model to gain more insight in the etiology of HHT1.
The partial loss of endoglin results in reduced angiogenesis [6], and defective collateral
artery formation after hind limb ischemia in Eng+/- mice [7], emphasizing the necessity of suf-
ficient endoglin expression for proper revascularization after tissue damage [8, 9]. Although
endoglin is mainly expressed by endothelial cells (ECs), several other cell types including
smooth muscle cells (SMCs) and mononuclear cells (MNCs) have endoglin on their cell sur-
face [10]. Due to the prominent role of endoglin in endothelial cell signaling and behavior,
HHT1 is generally considered a result of endothelial dysfunction. However, it has become
clear that the other cell types expressing endoglin, e.g. immune cells, may have a severe impact
on angiogenesis and tissue repair as well [11–13].
Previously we showed that Eng+/- mice display a diminished cardiac recovery after experi-
mentally induced myocardial infarction (MI) compared to wild type littermates [14]. The
reduced cardiac function is partially rescued when human control MNCs were injected into
the tail vein of Eng+/- mice. Interestingly, delivery of MNCs isolated from peripheral blood of
HHT1 patients did not increase heart function post-MI. Furthermore, endoglin heterozygosity
reduced the homing capacity of MNCs to the injured myocardium due to enhanced dipeptidyl
peptidase-4 (DPP4, also known as CD26) expression levels [14, 15]. This suggests that a defect
in MNCs, and not only endothelial cells, may play a role in the pathology of HHT1.
During the cardiac post-injury response, homing of MNCs to the site of injury is regulated
by the stromal cell-derived factor 1 (SDF1)-CXC chemokine receptor type 4 (CXCR4) axis.
SDF1 levels are increased within the first 24 hours after MI [16]. MNCs expressing the SDF1
receptor CXCR4 respond to this gradient by homing to the site of injury. The SDF1-CXCR4
axis is tightly controlled by the negative regulator DPP4. The catalytic enzyme DPP4 inacti-
vates SDF1 by cleaving off the first two of its amino-terminal peptides, thereby decreasing the
ability to recruit CXCR4-expressing MNCs towards the SDF1 gradient [17].
Another important target of DPP4 is the glucagon-like peptide-1 (GLP1). Preserving GLP1
via DPP4 inhibition stimulates insulin secretion and has therefore been the recent focus for
treatment of type 2 diabetes mellitus (T2DM). Interestingly, DPP4 inhibition was shown to
have multiple off-target effects that are potentially beneficial in the treatment of cardiovascular
disease [18, 19]. These DPP4 inhibitory actions are GLP1 independent and can range from
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having an anti-inflammatory effect [20, 21] to having a stimulating effect on MNC migration
[15] and differentiation [22, 23]. Pre-treating MNCs of HHT1 patients with the DPP4 inhibi-
tor Diprotin A (DipA) before injection into the circulation restored their homing to the ische-
mic myocardium [15]. Unfortunately, this is not a suitable protocol for clinical practice to pre-
treat MNCs of HHT1 patients, as cells have to be isolated in sufficient numbers from the
patients’ peripheral blood, treated with a DPP4 inhibitor and re-injected. Therefore, the aim of
this study is to determine whether systemic application of a DPP4 inhibitor is as effective in
restoring homing of Eng+/- MNCs to the site of ischemic injury.
Materials & methods
Animals and study design
Experiments and analyses were conducted on male endoglin wild type (Eng+/+, or referred to
as WT) and heterozygous (Eng+/-) transgenic mice and LysM-Cre-Engfl/+ / LysM-Cre-Engfl/fl
(endoglin targeted recombination under regulation of the Lysosome M promoter) transgenic
mice. All mouse strains were kept on a C57BL/6Jico background (Charles River). To obtain
the Eng-conditional knockout mouse lines, endoglin floxed mice (Engfl/fl) were cross-bred
with LysM-Cre [24, 25] animals to create the LysM-Cre-Engfl/+ and LysM-Cre-Engfl/fl mice. All
mouse experiments were approved by the regulatory authorities of Leiden University (the
Netherlands) and were in compliance with the guidelines from Directive 2010/63/EU of the
European Parliament on the protection of animals used for scientific purposes.
Humane endpoints were observed 5 days post-MI and onwards, as the following criteria
and symptoms: when mice displayed reduced mobility, decreased grooming, and/or impaired
reaction to external stimuli. In addition, for 3 days post-MI and onwards: when the wound
area displayed bleeding, swelling, redness and/or discharge, the mice would be euthanized by
carbon dioxide. The mice were weighed at the day of surgery and at the cardiac ultrasound
time points and euthanized when more than 15% loss of weight occurred. All mice that died
before meeting the criteria for euthanasia–just after myocardial infarction or within 10 days
post-MI–died because of cardiac rupture due to the deterioration of cardiac tissue after liga-
tion of the left anterior descending coronary artery. Animal health and behavior were moni-
tored on a daily basis by the research and/or animal care staff, all trained in animal care and
handling. Once animals reached endpoint criteria, the euthanasia was performed immediately
or at the least the same day when reported.
Myocardial infarction in mice
Myocardial infarction (MI) was experimentally induced as described before [15]. The mice
(n = 5–18 per group) were anesthetized with isoflurane (1.5–2.5%), intubated and ventilated,
after which the left anterior descending (LAD) coronary artery was permanently ligated by
placement of a suture. The mice were treated with the analgesic drug Temgesic, both pre-oper-
ative and 24 hrs post-operative to relieve pain. The mice were randomly allocated and treated
i.p. with either 100 μl distilled water daily (Milli-Q ultrapure, sterile water = MQ treated or
control group) or 100 μl DPP4 inhibitor (5 nMol, 55 μg/kg/day, Diprotin A, Sigma-Aldrich)
for the first 5 or 14 days post-MI.
Cardiac function measurements
Mice were anesthetized with isoflurane (1.5–2.5%), after which cardiac ultrasound was per-
formed and recorded with the Vevo 770 (VisualSonics, Inc., Toronto, CA) system, using a 30
MHz transducer (RMV707B). Imaging was performed on the longitudinal axis of the left
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ventricle using the EKV (Electrocardiography-based Kilohertz Visualization) in long axis view
imaging mode. The percentage ejection fraction was determined by tracing of the volume of
the left ventricle during the systolic and diastolic phase using the imaging software Vevo770
V3.0 (VisualSonics, Inc., Toronto, CA).
Cultured macrophages from mouse bone marrow
Monocytes were isolated from the mice femur and tibia and subsequently cultured in RPMI
1640 culture media (#11875093, Gibco, ThermoFisher Scientific), supplemented with 10% FBS
(#10270, Fetal Bovine Serum, Gibco, ThermoFisher Scientific) and 1 ng/ml granulocyte-mac-
rophage colony stimulating factor (GM-CSF, #315–03, Peprotech) to induce differentiation
into macrophages. Macrophage cultures from 3 mice of each genotype were pooled to obtain
sufficient protein to perform Western blot analysis.
Western blotting
Cultured macrophages were lysed on ice with cold radio immunoprecipitation assay (RIPA)
lysis buffer (in house) supplemented with protease inhibitors (Complete protease inhibitor
cocktail tablets, Roche Diagnostics, #11697498001) and protein concentration was measured
using BCA protein assay (Pierce BCA Protein Assay Kit, #23225, ThermoFisher Scientific).
Equal amounts of protein were loaded onto 10% SDS-polyacrylamide gel and transferred to an
Immobilon-P transfer membrane (# IPVH00010, PVDF membrane, Millipore). The blots
were blocked for 1 h using 10% milk in Tris-Buffered Saline and 0.1% Tween-20 solution and
incubated O/N with goat anti-mouse endoglin (1:1000 dilution, BAF1097, R&D Systems) or
mouse anti-β-Actin (1:10.000 dilution, A5441, Sigma-Aldrich). Blots were incubated for 1 h
with horse radish peroxidase anti-goat (goat anti-mouse IgG Poly-HRP Secondary Antibody
HRP conjugate, #32230, ThermoFisher Scientific) or anti-mouse (ECL mouse IgG, HRP-
linked whole Ab #NA931, Sigma-Aldrich, GE Healthcare, UK). Blots were developed in a
Kodak X-omat 1000 processor with Thermo Scientific SuperSignal West Dura (Extended
Duration Substrate) or SuperSignal West Pico and exposed to Fuji SuperRX medical X-ray
film. Analysis was performed using Image J (National Institute of Mental Health, Bethesda,
Maryland, USA).
Immunofluorescence and immunohistochemistry
Hearts were dissected from carbon dioxide-euthanized mice, 4, 14 or 28 days post-MI, fixated
overnight at 4˚C in 4% paraformaldehyde in PBS, and then washed with PBS, 50% EtOH and
70% EtOH for 1 h each, followed by embedding in paraffin wax. Sections of 6 μm thickness
were mounted onto coated glass slides (VWR SuperFrost Plus microscope slides). The paraffin
sections were stained as previously described [26] using antigen retrieval. Primary antibodies
were incubated overnight at 4˚C and directed against rat anti-mouse CXCR4 (clone 2B11,
dilution 1:100, # 551852, BD Pharmingen), rat anti-mouse MAC3 (CD107b, dilution 1:200,
#550292, BD Biosciences), rabbit anti-mouse Mannose Receptor (CD206, dilution 1:300,
ab64693, Abcam), rabbit anti-mouse alpha smooth muscle actin (αSMA, dilution 1:500,
ab5694, Abcam), rat anti-mouse PECAM-1 (CD31, dilution 1:800, #TLD-4E8, BD Pharmin-
gen) and goat anti-mouse cardiac troponin I (cTnI, 1:1000 dilution, #4T21, HyTest). Appropi-
ate fluorescent-labelled secondary antibodies (ThermoFisher Scientific) were incubated for 1.5
h, at 1:250 dilutions. The slides were mounted with Prolong Gold-DAPI Antifade (# P36931,
ThermoFisher Scientific) reagent.
Staining of fibrotic tissue was performed using Picrosirius Red (PSR) collagen staining
which includes deparaffinization, 1 h incubation with PSR solution (Sirius red F3B, CI 35780,
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Sigma Aldrich, in Picrine acid solution, # 690550, Klinipath), washing in acidified water and
mounting with Entellan (#107960, Merck) reagent. Staining of macrophages present in the
infarct border zone using rat anti-mouse MAC3 (CD107b, dilution 1:200, BD Biosciences) was
performed using avidin/biotin-based DAB peroxidase staining with the Vectastain ABC sys-
tem (Vector Laboratories) and hematoxylin counterstain to visualize cell nuclei.
Flow cytometry
After isolation of the hearts (n = 3–6), the left ventricle was excised and washed with PBS.
Heart tissue was digested in collagenase I (450 U/ml), collagenase XI (125 U/ml), DNase I (60
U/ml) and hyaluronidase (60 U/ml) (Sigma-Aldrich #H3506) at 37˚C for 1 h. Hearts were sub-
sequently homogenized through a 100-μm cell strainer (VWR-Corning #10054–458). MNCs
were isolated using Ficoll gradient (Histopaque-1083, Sigma, # 10831). Mouse MNCs from
either 50 μL of whole blood (treated 5min with erythrocyte lysis buffer, #930725, Alrijne hospi-
tal Leiden), or cells isolated from heart, bone marrow and spleen were labeled 1 h at room tem-
perature with anti-mouse CD11b (1:1600, BD Biosciences, #561114) and Ly6C (1:800, BD
Biosciences, #561085) for macrophages. Macrophages were identified as inflammatory M1:
Ly6G-/CD11b+/Ly6Chigh and regenerative M2 macrophages: Ly6G-/CD11b+/Ly6Clow as previ-
ously described [27]. Lymphocytes subsets were labeled with CD3e (1:800, BD Biosciences,
#558214), CD4 (1:800, Invitrogen, #MCD0422), CD8a (1:1600, BD Biosciences, #553032) and
Ly6G (1:1600, BD Biosciences, #560602) in buffer (2mM EDTA/ 0.5% BSA in PBS).
All acquisitions were performed on a LSRII flow cytometer (BD Biosciences) and analyzed
by FACS Diva software (BD Biosciences) and Flowing software 2.5.1 (Cell Imaging Core,
Turku Centre for Biotechnology, Finland). Gating strategies are provided in S7 Fig.
Morphometry
Infarct size was determined in Picrosirius Red staining images by calculating the percentage
infarct area of the total left ventricular area. Cell infiltration was determined by quantification
of 2 to 4 digital images per heart, at the border zone inside the infarcted area, taken at 40x mag-
nification (CaseViewer 3D Histech). The same method was used for quantification of capillary
and artery presence, except analysis was now at the outside borderzone of the infarct, where
cardiomyocytes were still viable. Data were blinded to the investigator and quantified by using
ImageJ v1.46r (NIH, USA).
Statistics
All results are expressed as mean ± standard error of the mean (SEM). Statistical significance
was accepted at p<0.05. Statistical significance was evaluated using one-way ANOVA testing
for difference between multiple groups. Adjustment for multiple comparisons with either
Tukey’s or Dunnett’s testing and unpaired students T-testing for testing between two groups,
using Graphpad Prism v6 for Windows. For data with groups where n = 3, non-parametric
testing was performed with Kruskal-Wallis ANOVA and Dunn’s multiple comparisons test.
Significant differences between survival curves were tested with a log-rank Mantel-Cox test.
Results
Involvement of macrophage-expressed endoglin during cardiac
regeneration
We have previously shown that HHT1 MNCs are impaired in their homing capacity towards
ischemic tissue [14]. To establish the endogenous contribution of MNCs to the Eng+/- phenotype,
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a LysM-specific mouse model for targeting myeloid cells (monocytes, macrophages and granulo-
cytes) was generated. Mice with either a heterozygous or homozygous deletion for LysM-specific
endoglin were analyzed. To validate recombination, MNCs were allowed to differentiate towards
macrophages in the presence of GM-CSF and western blot analysis showed reduced endoglin
expression in the LysM-Cre-Engfl/+, and a near absence of endoglin in the LysM-Cre-Engfl/fl mac-
rophages (Fig 1A and 1B).
The deletion of endoglin in monocytes did not affect survival post-MI (Fig 1C). Analysis of
cardiac function showed a trend towards reduced ejection fraction (EF) in the LysM-Cre-
Engfl/fl mice (Fig 1D, WT 34.07±3.65% vs LysM-Cre-Engfl/fl 22.73±4.30%, P = 0.09), suggesting
an involvement of endoglin in macrophage function during cardiac repair. However, since
cardiac dysfunction of the LysM-Cre-Engfl/fl phenotype post-MI is not as pronounced as the
reduction in EF seen in the Eng+/- mice after MI (Fig 1D, WT 32.45±4.06% vs. Eng+/- 17.98
±2.06%, P<0.05), we concluded that the injury response in HHT1 is likely to be an interplay
between a multitude of cell types, only partially represented by the LysM population. We there-
fore continued by analyzing the effect of DPP4 inhibitor treatment in the Eng+/- animals.
DPP4 inhibition restores the in vivo MNC homing capacity in Eng+/- mice
Macrophage infiltration is important for proper repair of damaged tissue [12, 28, 29]. Pre-
treatment of the HHT1-MNCs, expressing enhanced levels of DPP4, with a DPP4 inhibitor
prior to intravenous injection after experimentally induced MI in the mouse restored homing
of these cells to the infarct site. Therefore, we asked the question whether systemic administra-
tion of a DPP4 inhibitor would have the same effect, and treated mice with the DPP4 inhibitor
Diprotin A (DipA) systemically via intraperitoneal (i.p.) injection from day 0 till day 5 post-
MI. Flow cytometric analysis of blood samples at baseline revealed that the mice did not dis-
play any leukopenia because of endoglin heterozygosity (S1 Fig; gating strategy provided in
S7A and S7B Fig). At day 4 post-MI, during the peak of inflammatory cell influx [12], MNC
homing to the infarcted border zone is diminished in Eng+/- mice as shown by a decrease in
the number of CXCR4 positive MNCs in the infarct border zone (Fig 2A, quantification in B).
Systemic DipA treatment of Eng+/- mice did not affect survival up to 14 days post-MI (S2 Fig),
nor did it hematopoietic cell release from the bone marrow (data not shown), or granulocyte
presence in the blood or infarcted cardiac tissue (S3 Fig and gating strategy provided in S7C
Fig). DipA treatment did increase the homing of CXCR4 expressing cells to the infarct border
zone of Eng+/- heart to similar levels as observed in MQ treated WT mice (Fig 2B, WT control
154.50±17.21 and Eng+/- control 73.17±12.67 vs. Eng+/- DipA treated 157.00±11.61,
P = 0.0003). DipA treatment of control mice did not result in a significant increase in MNC
influx post-MI, suggesting that a maximal homing capacity is already achieved in these animals
(Fig 2B, WT control 154.50±17.21vs. WT DipA treated 178.00±6.50). The same restorative
effect on homing was observed for MAC3 positive macrophages. Quantification of MAC3+
cells in the infarct border zone showed a decreased number of macrophages in infarcted hearts
of Eng+/- mice, but their homing is enhanced upon systemic treatment with DipA (Fig 2C,
Eng+/- 45.17±5.73 vs. Eng+/- DipA treated 82.27±7.68, P = 0.002 and representative photos of
DAB staining in S4 Fig). As observed for the CXCR4 expressing cells, DipA treatment did not
affect the number of macrophages present in the infarcted hearts of wild type mice. Since there
are two main populations of macrophages involved in tissue repair [12], we analyzed the effect
of DPP4 inhibition on the inflammatory-like (M1) and regenerative-like (M2) macrophage
subtypes in the infarct border zone (Fig 2D). Analysis of the percentage of M2 in the total mac-
rophage population (represented by the percentage MAC3/CD206 positive cells) revealed a
decrease in M2 in Eng+/- mice compared to wild types (Fig 2E, WT 29.88 ±1.52% vs. Eng+/-
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12.34±1.64%, P<0.0001). After DipA treatment, there was a significant increase in the percent-
age of M2 macrophages within the total population of macrophages in both wild type and
Eng+/- mice, and consequently a decrease in M1 macrophages. Importantly, DipA was able to
Fig 1. Monocyte specific knock-out of endoglin does not recapitulate the Eng+/- phenotype. (A) Western blot analysis of
endoglin protein expression in LysM-Cre-Eng+/+, LysM-Cre-Engfl/+ and LysM-Cre-Engfl/fl cultured macrophages. A representative
experiment is shown. (B) Quantification of the Western blots for endoglin protein in LysM-Cre-Eng+/+, LysM-Cre-Engfl/+ and
LysM-Cre-Engfl/fl cultured macrophages in two independent experiments(macrophage cultures from 3 individual mice of each
genotype were pooled per western blot). (C) Kaplan-Meier survival curve of wild type (WT), LysM-Cre-Engfl/+ and LysM-Cre-Engfl/fl
mice 28 days post-MI (n = 6–10). (D) Cardiac function in percentage ejection fraction (%EF) 14 days post-MI. Cardiac function was
measured by ultrasound in long axis view (n = 5–9). Data are shown as mean ± SEM, *P<0.05.
https://doi.org/10.1371/journal.pone.0189805.g001
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Fig 2. DPP4 inhibitor treatment of Eng+/- mice restores homing of MNCs to injured myocardium at 4 days post-MI. (A) Representative
microscopy images of CXCR4 expression in the infarct border zone. White = surviving myocardium, black/grey area = infarcted myocardium.
Photos taken at 30x magnification. Scale bar: 50μm. CXCR4 = red, cTnI = white, DAPI nuclear staining = blue. (B) Quantification of CXCR4
expressing cells in the infarct border zone (n = 6–8). Data shown are mean ± SEM, *P<0.05. (C) Quantification of MAC3 positive cells in the
infarct border zone (n = 6–7). Data shown are mean ± SEM, *P<0.05. (D) Representative microscopy images of MAC3+/CD206- (%M1) and
MAC3+/CD206+ (%M2) expressing cells in the infarct border zone. Smaller panels: Top panel is the MAC3 signal, lower panel is the CD206
signal. Photos taken at 50x magnification. Scale bar: 20μm MAC3 = red, CD206 = green, DAPI = blue. (E) Quantification of the ratio of
DPP4 inhibition improves MNC homing and cardiac repair in a mouse model for HHT1
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restore the M1/M2 ratio in Eng+/- mice to WT levels. We further corroborated our findings by
flow cytometric analysis of the macrophage population in the infarct area. Inflammatory M1
(Ly6G-/CD11b+/Ly6Chigh) were increased in the Eng+/- at baseline compared to regenerative
M2 macrophages (Ly6G-/CD11b+/Ly6Clow). DPP4 inhibition showed a trend towards a
decrease in M1 macrophages (Fig 2F and gating strategy provided in S7D Fig). Thus, systemic
DipA treatment of Eng+/- mice restores homing of MNCs to, as well as the macrophage M1/
M2 balance in the injured heart 4 days post-MI.
DPP4 inhibition reduces infarct size
By treating the mice with DipA from day 0 to 5 post-MI, homing was stimulated during the
peak of inflammatory cell influx (Fig 3A). To assess the effect of DipA treatment on infarct size
we quantified the fibrotic area using Picrosirius red staining at day 14 post-MI (Fig 3B and
3C). As expected, control Eng+/- mice showed an increase in infarct size compared to WT con-
trols (Fig 3C, WT control 24.30±2.12% vs. Eng+/- control 46.60±9.33%, P = 0.009). Upon DipA
treatment, no effect on infarct size was detected in wild type animals (Fig 3C, WT DipA 27.41
±3.74%), however in Eng+/- mice a significant decrease in infarct size was observed (Fig 3C,
Eng+/- control 46.60±9.33% vs. Eng+/- DipA 27.02±3.04%, P = 0.02), which resulted in similar
infarct sizes as observed in the wild type mice.
Effect of DPP4 inhibition on cardiac function
Since DPP4 inhibition enhanced homing of circulating MNCs to the injured heart, reduced
infarct size and increased the number of regenerative macrophages present in the heart, we
investigated the effect of DipA treatment on cardiac function after MI using ultrasound at
baseline, and day 7 and day 14 after MI. Baseline analysis showed that cardiac function at base-
line was similar between wild type and Eng+/- mice (S5 Fig). At 7 and 14 days post-MI, control
treated Eng+/- animals showed a significantly lower cardiac EF compared to control treated
wild type mice (Fig 4A, WT control day 7; 31.01±4.32% vs. Eng+/- control day 7;18.68±1.84%
and WT control day 14; 32.45±4.06% vs. Eng+/- control day 14; 17.98±2.06%). Treating wild-
type animals with DipA did not result in significant changes in the EF (Fig 4B, also compare to
4A, WT DipA treated day 7; 27.53±3.24% vs. WT DipA treated day 14; 34.15±2.69%). Interest-
ingly, DipA treatment in Eng+/- did result in normalization of the EF to the same values as WT
animals at day 7 (Fig 4B, Eng+/- DipA treated day 7; 26.94±5.65%), although at day 14, it was
less pronounced (Fig 4B, Eng+/- DipA treated day 14; 22.02±3.65%). Nevertheless, these func-
tional data coincide with the reduced infarct size observed in Fig 3.
As we observed that endoglin heterozygosity skews the M1/M2 ratio towards a more
inflammatory profile, both homing and/or differentiation of Eng+/- MNCs might be delayed.
Therefore, we prolonged the daily DipA treatment from 5 till 14 days post-MI. Extended
DPP4 inhibition resulted in a similar decrease in cardiac function in wild type mice compared
to short term (5 days post-MI) treated mice (Fig 4C). While initially DPP4 inhibition in the
Eng+/- animals improves cardiac function, Eng+/- mice showed a gradual reduction of cardiac
function in the 6 month follow-up (ΔEF in Fig 4C and %EF is provided in S6 Fig). Thus, nei-
ther short term nor prolonged DipA treatment resulted in a long term beneficial effect on
heart function in Eng+/- mice.
MAC3+/CD206- (%M1) and MAC3+/CD206+ (%M2) expressing cells in the infarct border zone (n = 6–7). (F) Flow cytometric analysis of the
macrophage population in the infarct area, ratio of inflammatory M1(Ly6G-/CD11b+/Ly6Chigh) versus regenerative M2 macrophages (Ly6G-/
CD11b+/Ly6Clow) (n = 3–6, non-parametric ANOVA testing). Control = MQ treated, DipA = Diprotin A treated group. Data shown are
mean ± SEM, *P<0.05.
https://doi.org/10.1371/journal.pone.0189805.g002
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DPP4 inhibition increases angiogenesis but decreases vessel
maturation in Eng+/- animals
Since neoangiogenesis is important for cardiac repair post-MI, we investigated the effect of
DipA treatment on vascularization by staining the hearts for PECAM-1 and αSMA and ana-
lyzed the presence of capillaries and arteries in the infarct border zone. The number of capillar-
ies in the Eng+/- mice was increased compared to wild type animals (Fig 5A). In both wild type
as well as Eng+/- mice, DipA treatment further increased the number of capillaries present in
the border zone (Fig 5A, Eng+/- 61.63±1.43 vs. Eng+/- treated 74.30±1.74, P = 0.001). Surpris-
ingly, the number of arteries in the infarct border zone was significantly lower in the DPP4
inhibitor treated Eng+/- mice (Eng+/- 11.88±0.63 vs. Eng+/- treated 6.38±0.97, P = 0.003), which
may suggest that vessel maturation or arteriogenesis is impaired (Fig 5B).
Fig 3. DPP4 inhibitor treatment reduces infarct size. (A) Experimental protocol and treatment overview. At day 0, MI is induced and DPP4
inhibition is started (shown in green) till day 5 post-MI by intraperitoneal (i.p.) injection of DipA (treatment group) or distilled water (control group).
Cardiac echography was performed at day 7 and 14 post-MI. (B) Histological analysis of the infarct size by Picrosirius red staining for collagen
(n = 5–9). Transverse sections of left ventricle, photos taken at 1.0x magnification. Infarct area = dark pink, healthy myocardium = light pink,
blood cells = yellow. (C) Quantification of Picrosirius red staining in left ventricle (LV). Mice were subjected to MI and treated with either distilled
water or DipA from day 0 till day 5 by daily i.p. injection (n = 5–9). Control = MQ treated, DipA = Diprotin A treated group. Data shown are
mean ±SEM, *P<0.05.
https://doi.org/10.1371/journal.pone.0189805.g003
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Fig 4. DipA treatment does not maintain improved cardiac function of Eng+/- mice after MI. (A) Experimental
overview and percentage EF at 7 and 14 days post-MI of control treated mice, measured by ultrasound via left
ventricle tracing (n = 5–9). Data shown are mean ± SEM, *P<0.05. (B) Percentage EF 7 and 14 days post-MI of DipA
treated mice, measured by ultrasound via left ventricle tracing. Note that the control WT and Eng+/- groups are the
repeat of measurements used for Fig 1D (n = 9–11). Data shown are mean ± SEM, *P<0.05. (C) Long term treatment
overview and Δ%EF. DipA treatment (shown in green) up to 14 days post-MI and cardiac function with extended
follow-up of 6 months (n = 5–11). Data depicted as ΔEF are the EF at the time point indicated on the x-axis compared
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Macrophage presence in the ventricular wall is prolonged in Eng+/- mice
Tissue repair is a tightly controlled process, with a delicate balance between the influx of
inflammatory cells needed to remove cell debris after ischemia, and their resolution thereafter
when damaged tissue is repaired. A prolongation of the inflammatory phase is detrimental for
to EF measured at day 7 post-MI. Cardiac function was measured by ultrasound via left ventricle tracing.
DipA = DPP4 inhibitor Diprotin A, US = Ultrasound measurement. Control = MQ treated, DipA = Diprotin A treated
group. Data shown are mean ± SEM, *P<0.05.
https://doi.org/10.1371/journal.pone.0189805.g004
Fig 5. DPP4 inhibition affects angiogenesis in the infarct border zone post-MI. (A) Capillaries in infarct border zone, day 14 post-MI.
Quantification of PECAM-1 positive vessels per area (n = 4–6). Data shown are mean ± SEM, *P<0.05. (B) Arteries in infarct border zone,
day 14 post-MI. Quantification of PECAM-1/αSMA positive vessels per area (n = 4–6). Data shown are mean ± SEM, *P<0.05. (C)
Quantification of total macrophage (MAC3) number in day 14 post-MI hearts (n = 4–6). Data shown are mean ± SEM, *P<0.05. (D)
Quantification of MAC3+/CD206+ (%M2) expressing cells in the infarct border zone 14 days post-MI (n = 3–6). Control = MQ treated,
DipA = Diprotin A treated group. Data shown are mean ± SEM, *P<0.05.
https://doi.org/10.1371/journal.pone.0189805.g005
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tissue repair. Interestingly, a significantly higher number of macrophages was observed in the
infarct border zone of the Eng+/- mice compared to the wild type mice 14 days post-MI (Fig
5C, WT 7.06±0.97 vs. Eng+/- 25.13±2.76, P<0.0001). DipA treatment of Eng+/- did not reduce
the total number of macrophages to wild type levels.
Analyzing the macrophage phenotypes, we observed a disbalance in the M1/M2 ratio in the
hearts of Eng+/- mice 4 days post-MI. Therefore, macrophage quantity and subtype in the heart
was also analyzed 14 days post-MI. Interestingly, Eng+/- DipA treated mice showed an increase
in M2 levels reaching wild type levels (Fig 5D WT 51.7% vs. Eng+/- treated 52.7%), while in
wild type mice DipA treatment resulted in a significant drop in the percentage of M2 cells (Fig
5D WT 51.7% vs. WT treated 22.0%, P = 0.04). These results suggest that there is a prolonged
inflammatory response and possibly an impaired resolution of inflammation in Eng+/- mice,
and the macrophage balance can be skewed towards the M2 subtype by DPP4 inhibition.
Discussion
In this study we demonstrate that after MI, the decrease in myocardial function observed in
our HHT1 animal model is not solely caused by a disturbed endothelium response, but also in
part by impaired MNC function. MNC homing and differentiation into inflammatory and
regenerative macrophages is important for proper tissue repair. In our previous research, we
found that MNC homing towards the ischemic myocardium is severely affected by endoglin
heterozygosity, together with enhanced DPP4 levels [15]. Here, we demonstrate that homing
of MNCs to the ischemic myocardium could be restored by systemic DPP4 inhibition.
Although DipA treatment did reduce the infarct size in Eng+/- mice to similar levels as in wild
type animals, it did not result in long term improvement of EF. Detailed analysis of the
infarcted ventricle demonstrated that neovascularization was increased in the Eng+/- infarct
border zone upon DPP4 inhibition, while arteriogenesis or vessel maturation was dramatically
decreased. Furthermore, analyzing the macrophage subsets, a prolonged presence of inflam-
matory-like macrophages (M1) was observed. We therefore conclude that the inflammatory
and regenerative function of Eng+/- macrophages is affected. Interestingly, DPP4 inhibition
could restore this M1/M2 imbalance to WT levels.
Complete endoglin deficiency in mice results in embryonic lethality around mid-gestation
due to cardiovascular defects and the formation of enlarged, fragile vessels [4]. Eng+/- mice or
endothelial deletion of endoglin in adult mice results in a relatively mild phenotype. Only after
a secondary hit like induction of tissue damage or inflammation, the impairments of endoglin
deficiency become apparent in the form of reduced angiogenesis and the development of
AVMs [30–32]. In the current study, we observed that the macrophage specific deletion of Eng
did not result in similar levels of cardiac deterioration as found in Eng+/- animals, implying a
multifactorial nature of HHT1. This emphasizes the need for endoglin heterozygosity to be
present in all cell types of the heart to recapitulate the HHT1 disease phenotype.
Furthermore, we show that the homing capacity of MNCs in the Eng+/- mice could be
restored by systemic DPP4 inhibitor treatment. In cardiovascular patients an association was
found between increased DPP4 presence on MNCs and poor recovery after coronary interven-
tion [33]. Together with our observation of decreased homing capacity of the MNCs, HHT1
now proves to affect other cell types and functions as well, in particular the lymphocytes and
monocytes [31, 32, 34, 35]. Macrophages are an important subfraction of the MNC population,
as macrophages have both inflammatory and angiogenic capacity and are essential in tissue
regeneration and remodeling [28]. The shift of the inflammatory-like macrophages (M1) to
the regenerative-like macrophages (M2) is essential for optimal resolution of inflammation
[36]. Immune function and the angiogenic capacity of macrophages are most likely impaired
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in Eng+/- mice [37, 38]. Recent studies suggested that there is an intrinsic inflammatory defect
in HHT1 patients as well. Investigators report leukopenia, increased risk of infection [34] and
impaired endoglin upregulation in activated monocytes of HHT1 patients [35]. We now
observed an increased ratio of M1/M2 macrophages in Eng+/- mice hearts post-MI, which may
indicate that the increase in M1 macrophages is due to either impaired differentiation of the
M1 towards M2 macrophages, or decreased homing capacity of M2 macrophages. In renal
ischemia-reperfusion injury, the same disbalance in M1/M2 was also reported in Eng+/- mice
[39]. DPP4 inhibition has been shown to shift the M1/M2 balance towards more reparative
macrophages [22, 23]. We show that in Eng+/- mice DipA treatment restored both the total
number of macrophages as well as the M1/M2 ratio. This effect was maintained up to 10 days
after cessation of DPP4 inhibitor treatment. The shift of the macrophage population towards
M2 induced by DPP4 inhibition was also observed by Brenner et al. [22], when analyzing mac-
rophage presence in the aortic walls of ApoE-/- mice in a model for atherosclerosis. Likewise, a
reduction of atherosclerotic lesions [20] and total macrophage presence was reported in
ApoE-/- mice treated with DPP4 inhibitor, together with a reduction in smooth muscle cell
proliferation [40]. DPP4-null mice had an increased expression of M2 genes [41] and further-
more, DPP4 inhibition had anti-inflammatory effects on macrophages in general by decreas-
ing pro-inflammatory NFκB signaling [42]. An increase in M2 macrophages was also observed
upon DPP4 inhibitor treatment in another atherosclerosis model using LDLR-/- mice [43],
moreover, a recent meta-analysis showed a decreased infection rate in T2DM patients treated
with a DPP4 inhibitor [44]. Here we show for the first time, to our knowledge, that DPP4 inhi-
bition polarizes the M1/M2 ratio towards a more regenerative phenotype in a mouse model
for HHT1. Furthermore, our data suggests that endoglin heterozygosity not only impairs hom-
ing of the MNCs, but affects proper differentiation and/or function of the macrophages, as we
find more M1 at the infarct site and a decrease in resolution of immune cells 14 days post-MI
in Eng+/- animals.
In addition to improved homing of circulating (stem) cells, we and others show that DPP4
inhibition significantly stimulated vascularization and cardiac repair [45–47]. In conjunction,
an increase in capillary number was observed at the infarct border zone, confirming an
increase in endothelial regeneration, possibly by enhanced presence of regenerative M2 mac-
rophages. Interestingly, the number of arteries present was found to be significantly lowered in
the DPP4 inhibitor treated Eng+/- mice. Vessel maturation is known to be affected in Eng+/-
mice, due to dysfunctional mural cells and pericytes [48, 49]. Our results therefore suggest that
DPP4 inhibitor treatment most likely further impairs vessel maturation in Eng+/- mice, due to
its involvement in vascular smooth muscle cell recruitment [50, 51].
DPP4 inhibitors have been reported to increase cardiomyocyte survival, however the exact
mechanism is not yet fully understood. DPP4 has many targets besides SDF1, like atrial natri-
uretic peptide (ANP)- a protein associated with cardiomyocyte survival [52]. DPP4 inhibition
might therefore decrease the inactivation of ANP by DPP4, and contribute to cardiomyocyte
survival/protection. Furthermore, when MI was performed in DPP4-/- mice, these mice show
an increased survival compared to DPP4+/+ mice [52]. DPP4 inhibitor treatment in previous
reports already showed a modest, albeit not significant gain of cardiac function in wild type
mice after MI [53]. Interestingly, at day 14 post-MI the infarct size in Eng+/- mice treated with
DipA was significantly smaller and similar in size compared to wild type control levels. Con-
cordantly, we observed an initial increase in EF upon DipA treatment. However, improved
cardiac function in Eng+/- mice was not preserved at day 14 post-MI. These results suggest that
DPP4 inhibition conveys a decrease of the fibrotic response in Eng+/- animals, resulting in a
reduced infarct size, though this is not reflected in a sustained improvement of heart function.
This could be in part explained by the fact that although capillary presence is increased, in
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HHT1 endothelial functionality is impaired, forming leaky vessels. Secondly, the misbalanced
MNC population present in HHT1 might result in an exaggerated and prolonged immune
response, which is likely to disturb tissue repair.
We hypothesized that when homing of Eng+/- MNCs to the infarct site was restored, car-
diac function would improve, as was observed in wild type animals [46, 53]. Although
increased homing and a decrease in infarct size were observed, this did not correlate with a
long term positive effect on cardiac function. The Eng+/- mice showed either a reduced dif-
ferentiation towards, or presence of the regenerative macrophage subtype and interestingly
this level could be corrected by DPP4 inhibition. However, although the fibrotic response
was restored to wild type levels and MNC recruitment was re-established, the Eng+/- mice
still show a decrease in cardiac function. This suggests that the impaired function of the
Eng+/- MNCs that homed to the infarct site still exists. Combining DPP4 inhibition with
G-CSF treatment for enhanced MNC recruitment, Zaruba et al. showed that ameliorated
MNC homing resulted in a significant increase in cardiac function in mice. However, test-
ing this treatment in patients suffering from MI, the combination failed to show any benefi-
cial effect on cardiac function [54, 55].
How DPP4 inhibition affects MNC function is still unclear. DPP4 inhibition is already
being tested in several clinical trials in cardiovascular disease (CVD), and meta-analyses of the
risks involved have proven to be varied in outcome. Several meta-analyses have been per-
formed in the field of T2DM. Upon DPP4 inhibition, no increase in CVD was observed in
T2DM patients, but risk of infection was reduced [44]. In addition, although no effect was
seen on cardiovascular mortality, short term DPP4 inhibition reduced chances of MI events,
while long term treatment showed a possible increase in heart failure cases [56, 57]. Other
meta-analyses showed either no effect or a reduction of cardiovascular events, also with long
term treatment [58–61].
As described in this study, DPP4 inhibition positively affects cardiac fibrosis and initially,
also cardiac function. We showed by using a PSR staining that fibrosis is enhanced in Eng+/-
mice and decreases upon DPP4 inhibition. A relation between DPP4 inhibition and reduction
in fibrosis was also demonstrated in a kidney model [62]. Furthermore, inhibition of
DPP4-positive fibroblasts reduced scarring of murine dermal wounds [63] and DPP4 inhibi-
tion also mediated antifibrotic effects in dermal fibroblasts [64]. DPP4 inhibition is shown to
be cardioprotective in several studies (reviewed in Grilo et al. [65]). A study overexpressing
DPP4 resulted in promoted mammary tumorigenesis and transformation of epithelial cells
[66], altogether indicating DPP4 inhibition is the way forward.
DPP4 and its inhibition has a multitude of functions and effects, many of which are still
poorly understood. This is exemplified by the study from Zhu et al. [67], where they show that
DPP4 is able to target neuropeptide Y and peptide YY in the cardiac nerves, proteins that can
result in activation of cardiac fibroblasts. To the contrary, many anti-fibrotic aspects have been
described, and by various mechanisms; DPP4 inhibitors were reported to lower active TGFβ
(via reduction of DPP4 -CIM6PR membrane receptor interaction) and also decrease fibronec-
tin expression [68–70]. Together, the beneficial effects of DPP4 inhibition on MNC homing,
reduction in fibrosis and restoration of regenerative macrophage differentiation could provide
a suitable treatment for general tissue repair in HHT1 patients. However, this study suggests
that treating HHT1 patients with a DPP4 inhibitor post-MI should not be considered as
monotherapy, but ought to be combined with additional MNC stimulating agents and/or
arteriogenic stimulation. Although DPP4 inhibition is an accepted treatment in T2DM
patients, a better understanding of its mode of action should first be gained before further con-
ducting clinical trials for applying this treatment on any other disease or disorder like HHT1.
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Supporting information
S1 Fig. Eng+/- mice do not display leukopenia. Flow cytometric analysis of the major leuko-
cyte subsets in the circulation of the mice groups at day 0 (pre-MI and pre-DipA treatment).
Leukocytes labeled for anti-mouse CD3, CD3+/CD4+, CD3+/CD8+ and CD11b+/Ly6G-
(n = 3–6, non-parametric ANOVA testing). Control = MQ treated, DipA = Diprotin A treated
group. Data shown are mean ± SEM, P<0.05.
(TIF)
S2 Fig. DPP4 inhibition does not affect survival of WT and Eng+/- mice. Kaplan-Meier
curve of WT and Eng+/- mice 14 days post-MI. Graph depicts percentage of surviving WT and
Eng+/- mice, control and DipA treated animals (n = 12–18). Control = MQ treated,
DipA = Diprotin A treated group.
(TIF)
S3 Fig. The granulocyte subset is not affected in Eng+/- mice at baseline or by DipA treat-
ment 4 days post-MI. Flow cytometric analysis of the granulocyte subset in the circulation of
the mice at (A) day 0 (pre-MI and pre-DipA treatment) and (B) day 2 and (C) 4 post-MI in
the circulation. (D) Granulocytes isolated from the infarcted part of the LV 4 days post-MI.
Leukocytes labeled with anti-mouse CD11b, Ly6G. Granulocytes were identified as the
CD11b-/Ly6G+ population of the live gate (n = 3–6, non-parametric ANOVA testing).
Control = MQ treated, DipA = Diprotin A treated group. Data shown are mean ± SEM,
P<0.05.
(TIF)
S4 Fig. MAC3 expressing cells in the infarct border zone 4 days post-MI. Transversal sec-
tions of mouse hearts were stained for macrophage marker MAC3 using immunohistochemis-
try (n = 6–7). Photos taken at 15x magnification. MAC3 = brown, nuclei = blue.
(TIF)
S5 Fig. Eng+/- mice show no difference in baseline ejection fraction. Baseline cardiac func-
tion in percent ejection fraction (%EF) between WT and Eng+/- mice (n = 4). Cardiac function
was measured by ultrasound. Data shown are mean ± SEM, P<0.05.
(TIF)
S6 Fig. DPP4 inhibition does not improve cardiac function long term. Percentage EF 7, 14,
28 days and 6 months post-MI of WT(+/+) and Eng+/- (+/-) mice, control (Milli-Q ultrapure
sterile water, MQ) and DipA treated animals. EF was measured by ultrasound and analyzed by
left ventricle tracing (n = 5–11). Data shown are mean ± SEM, P<0.05.
(TIF)
S7 Fig. Flow cytometry gating strategy T-cells, monocytes and macrophages. (A) Gating
strategy for CD3, 4 and 8 T-cells in the blood. The first gating step is a gate for live cells using
FSC and SSC. T-cells are subsequently identified using CD3. T-cells subsets are then identified
with CD4 and CD8.
(B) Monocytes gating strategy in the blood. The first gating step is a gate for live cells using
FSC and SSC. The second gating step is for monocytes, identified by CD11b positive and Ly6G
negative labeling.
(C) Granulocyte gating strategy in the blood. The first gating step is a gate for live cells using
FSC and SSC, the granulocytes are subsequently identified by Ly6G.
(D) Macrophage subsets gating strategy from MNCs isolated from the left ventricle. The first
gating step is a gate for live cells using FSC and SSC, the monocytes are identified by CD11b
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positive and Ly6G negative labeling. The inflammatory-like M1 macrophages are then subse-
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